Sfoglia per AUTORE
PAZ-ARES L
Collezione AOU San Luigi di Orbassano

  

Items : 14

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. in Future oncology (London, England) / Future Oncol. 2025 Mar 24:1-12. doi: 10.1080/14796694.2025.2474789.
2025
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032.
2024
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Aix SP; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Nishino K; Yoh K; Shih JY; Chik JYK; Moro-Sibilot D; Puri T; Chacko Varughese S; Frimodt-Moller B; Visseren-Grul C; Reck M;

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529-2. doi: 10.1016/j.jtho.2024.12.010.
2024
ASL Cuneo 2
ASL Asti
AOU San Luigi di Orbassano

Novello S; Scagliotti G; Righi L; Vallone S; Malapelle U; Volante M; Giannarelli D; Mohorcic K; Meoni G; Scotti V; Linardou H; Bettini AC; Ramizi KM; Secen N; Comanescu A; Felip E; Paz-Ares L; Pignataro D; Araujo A; Barbieri V; Mazilu L; Buffoni L; Taveggia PA; Simionato F; Roca E; Sini C; Tabbò F; Reale ML; Zambelli V; et alii...

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. in Lancet (London, England) / Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7.
2023
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform. in Scientific reports / Sci Rep. 2022 May 18;12(1):8342. doi: 10.1038/s41598-022-12056-0.
2022
AOU San Luigi di Orbassano

Morfouace M; Novello S; Stevovic A; Dooms C; Janži? U; Berghmans T; Dziadziuszko R; Gorlia T; Felip E; Paz-Ares L; Mazieres J; O'Brien M; Bironzo P; Vansteenkiste J; Lacroix L; Dingemans AC; Golfinopoulos V; Besse B;

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19.
2021
AOU San Luigi di Orbassano

Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; et alii...

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2020 Jun;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006. Epub 2020 Mar 14.
2020
AOU San Luigi di Orbassano

Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV;

Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Jan 20;38(3):271-280. doi: 10.1200/JCO.19.01348. Epub 2019 Nov 21.
2020
AOU San Luigi di Orbassano

Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümü? M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L; Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümü? M; Laktionov K; Hermes B; Cicin I; et alii...

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
2019
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;

Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2019 Dec;14(12):2109-2119. doi: 10.1016/j.jtho.2019.07.025. Epub 2019 Aug 6.
2019
AOU San Luigi di Orbassano

Dingemans AC; Hendriks LEL; Berghmans T; Levy A; Hasan B; Faivre-Finn C; Giaj-Levra M; Giaj-Levra N; Girard N; Greillier L; Lantuéjoul S; Edwards J; O'Brien M; Reck M; Smit EF; Van Schil P; Postmus PE; Ramella S; Lievens Y; Gaga M; Peled N; Scagliotti GV; Senan S; Paz-Ares L; Guckenberger M; McDonald F; Ekman S; Cufer T; Gietema H; et alii...

Lung cancer: current therapies and new targeted treatments. in Lancet (London, England) / Lancet. 2017 Jan 21;389(10066):299-311. doi: 10.1016/S0140-6736(16)30958-8. Epub 2016 Aug 27.
2017
AOU San Luigi di Orbassano

Hirsch FR; Scagliotti GV; Mulshine JL; Kwon R; Curran WJ Jr; Wu YL; Paz-Ares L;

Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2017 Feb;104:45-51. doi: 10.1016/j.lungcan.2016.12.007. Epub 2016 Dec 12.
2017
AOU San Luigi di Orbassano

Paz-Ares LG; Zimmermann A; Ciuleanu T; Bunn PA; Antonio BS; Denne J; Iturria N; John W; Scagliotti GV;

2014
AOU San Luigi di Orbassano

Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG;

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):690-6.
2005
AOU San Luigi di Orbassano

Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L;